Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2025-11-04 00:00:00 ET · period of report 2025-10-31 · accession 0001376043-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-04 | 2025-10-31 | TVTX | Coughlin Timothy | Dir | M - OptEx | $16.95 | +18.0K | 63.5K | +40% | +$305.0K |
| D | 2025-11-04 | 2025-10-31 | TVTX | Coughlin Timothy | Dir | S - Sale+OE | $35.03 | -18.0K | 55.5K | -24% | -$630.5K |
| DM | 2025-11-04 | 2025-10-31 | TVTX | Coughlin Timothy | Dir | M - OptEx | $0.00 | -18.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-31 | M | A | 10,000 | $17.44 | 73,500 | D | — | — | |
| 2 | Common | Common Stock | 2025-10-31 | S | D | 18,000 | $35.03 | 55,500 | D | — | — | (F2) The weighted average sale price for the transaction reported was $35.0334, and the range of prices were between $35.00 and $35.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 3 | Common | Common Stock | 2025-10-31 | M | A | 8,000 | $16.33 | 63,500 | D | — | — | |
| 4 | Derivative | Director stock option (right to buy) | 2025-10-31 | M | D | 8,000 | $0.00 | 0 | D | $16.33 · — to 2026-05-17 | 8,000 Common Stock | (F3) The stock option is fully vested and exercisable. |
| 5 | Derivative | Director stock option (right to buy) | 2025-10-31 | M | D | 10,000 | $0.00 | 0 | D | $17.44 · — to 2027-05-16 | 10,000 Common Stock | (F3) The stock option is fully vested and exercisable. |